STOCK TITAN

Humana (HUM) Financials

HUM NYSE
Trailing 12 months to September 30, 2026
Revenue $154.2B +22.0% YoY
Net Income $1.2B -3.5% YoY
EPS (Diluted) $10.30 -3.6% YoY
Free Cash Flow $3.1B +102.9% YoY
Market Cap $54.0B as of Nov 13, 2026
Price / Sales 0.4x on $154.2B revenue, trailing 12 months to September 30, 2026
Price / Earnings 43.4x on $1.2B net income, trailing 12 months to September 30, 2026
Price / Book 2.9x on $18.8B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HUM SEC filings page.

Humana Inc. (HUM) reported $154.2B in revenue over the twelve months to Sep 30, 2026, up 22.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HUM FY2025

Humana is growing revenue while cash generation and profitability weaken, making expansion increasingly less productive.

From FY2023 to FY2025, revenue rose 21.9% while operating income fell 32.6%, showing that added scale did not translate into stronger operating earnings. Net income fell 52.3% over the same span as operating margin declined 1.7 percentage points, indicating a broad deterioration rather than a one-line earnings distortion.

Cash conversion became less dependable: operating cash flow was 245.7% of net income in FY2024 but only 77.5% in FY2025. After capital expenditures of $546M, just $375M remained as free cash flow, leaving accounting profit far less available for reinvestment or distributions.

Cost growth outpaced sales in FY2025: revenue increased 10.1% while selling, general and administrative expense rose 12.8%, consistent with the operating-margin compression. The balance sheet still shows short-term coverage at a 2.0x current ratio, but long-term debt increased 11.0%, adding financing weight as returns on assets slipped to 2.4%.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 49 / 100
Financial Health Score 49/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Humana Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
48

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Humana Inc. scores 48/100 on it among other operating companies.

Growth
65

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Humana Inc. scores 65/100 on it among other operating companies.

Leverage
25

Humana Inc.'s net debt of $8.2B, being $12.4B of long-term debt less $4.2B of cash, came to 2.40 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Humana Inc. scores 25/100 among other operating companies.

Liquidity
59

Humana Inc. held $2.00 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 2.00. Liquidity ranks operating companies on that ratio, and Humana Inc. scores 59/100 among other operating companies.

Cash Flow
31

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Humana Inc. scores 31/100 on it among other operating companies.

Returns
68

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Humana Inc. scores 68/100 on it among other operating companies.

Altman Z-Score Safe
5.11

Humana Inc. scores 5.11, well above the 2.99 safe threshold. The largest contribution to the score comes from revenue of $129.7B against total assets of $48.9B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
5/8

Humana Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality Mixed
0.78x

For every $1 of reported earnings, Humana Inc. generates $0.78 in operating cash flow ($921.0M OCF vs $1.2B net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Adequate
4.29x

Humana Inc. earns $4.29 in operating income for every $1 of interest expense ($2.7B vs $631.0M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$41.2B
YoY+26.1%
QoQ+0.7%
5Y CAGR+14.7%
10Y CAGR+11.6%

Humana Inc. generated $41.2B in revenue in Q3 2026. This represents an increase of 26.1% from the same quarter a year earlier. Against the prior quarter it is up 0.7%.

EBITDA
$233.0M
YoY-59.3%
QoQ-84.7%
5Y CAGR-22.0%

Humana Inc.'s EBITDA was $233.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 59.3% from the same quarter a year earlier. Against the prior quarter it is down 84.7%.

Net Income
$162.0M
YoY-16.9%
QoQ-76.7%
5Y CAGR-36.2%
10Y CAGR-9.7%

Humana Inc. reported $162.0M in net income in Q3 2026. This represents a decrease of 16.9% from the same quarter a year earlier. Against the prior quarter it is down 76.7%.

EPS (Diluted)
$1.33
YoY-17.9%
QoQ-76.8%

Humana Inc. earned $1.33 per diluted share (EPS) in Q3 2026. This represents a decrease of 17.9% from the same quarter a year earlier. Against the prior quarter it is down 76.8%.

Cash & Balance Sheet

Free Cash Flow
$2.0B
YoY+142.3%
QoQ+10.5%
5Y CAGR-4.2%
10Y CAGR-7.4%

Humana Inc. generated $2.0B in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 142.3% from the same quarter a year earlier. Against the prior quarter it is up 10.5%.

Cash & Debt
$6.9B
YoY+28.7%
QoQ+0.6%
5Y CAGR+10.0%
10Y CAGR+0.2%

Humana Inc. held $6.9B in cash against $11.6B in long-term debt as of Q3 2026.

Dividends Per Share
$0.89
YoY0.0%
QoQ0.0%

Humana Inc. paid $0.89 per share in dividends in Q3 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding
120M
YoY-0.1%
QoQ0.0%
5Y CAGR-1.3%
10Y CAGR-2.1%

Humana Inc. had 120M shares outstanding in Q3 2026. This represents a decrease of 0.1% from the same quarter a year earlier. It is unchanged from the prior quarter.

Margins & Returns

Operating Margin
0.2%
YoY-1.1pp
QoQ-3.1pp
5Y change-2.9pp

Humana Inc.'s operating margin was 0.2% in Q3 2026, reflecting core business profitability. This is down 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 3.1 percentage points.

Net Margin
0.4%
YoY-0.2pp
QoQ-1.3pp
5Y change-7.0pp
10Y change-2.9pp

Humana Inc.'s net profit margin was 0.4% in Q3 2026, showing the share of revenue converted to profit. This is down 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.

Return on Equity
0.9%
YoY-0.2pp
QoQ-2.8pp
5Y change-8.6pp
10Y change-3.1pp

Humana Inc.'s quarterly ROE was 0.9% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.8 percentage points.

Gross Margin

Not reported for Q3 2026.

Capital Allocation

Share Buybacks
$2.0M
YoYn/m
QoQ+100.0%
5Y CAGR-7.8%
10Y CAGR0.0%

Humana Inc. spent $2.0M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 100.0%.

Capital Expenditures
$137.0M
YoY+1.5%
QoQ+3.8%
5Y CAGR-15.9%
10Y CAGR-0.1%

Humana Inc. invested $137.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 1.5% from the same quarter a year earlier. Against the prior quarter it is up 3.8%.

R&D Spending

Not reported for Q3 2026.

HUM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HUM quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$41.2B+26.1%$40.9B+26.2%$39.6B+23.5%$32.5B+11.3%$32.6B+11.1%$32.4B+9.6%$32.1B+8.4%$29.2B+10.4%
SG&A Expenses$4.6B+12.6%$4.0B+12.2%$4.0B+19.1%$4.4B+6.5%$4.1B+22.3%$3.5B+12.7%$3.4B+11.1%$4.2B+8.9%
Operating Income$75.0M-81.3%$1.4B+23.9%$1.8B-12.9%-$808.0Mn/m$400.0M-45.1%$1.1B-3.8%$2.0B+62.9%-$543.0Mn/m
EBITDA$233.0M-59.3%$1.5B+19.0%$1.9B-12.7%-$644.0Mn/m$573.0M-38.9%$1.3B-5.7%$2.2B+52.0%-$335.0Mn/m
Interest Expense$217.0M+29.2%$197.0M+25.5%$193.0M+20.6%$146.0M-11.0%$168.0M-0.6%$157.0M-6.5%$160.0M+0.6%$164.0M+12.3%
Income Tax$40.0Mn/m$238.0M+33.0%$395.0M-2.7%-$249.0Mn/m-$86.0M-155.5%$179.0M-19.7%$406.0M+61.8%-$216.0Mn/m
Net Income$162.0M-16.9%$694.0M+27.3%$1.2B-4.7%-$796.0Mn/m$195.0M-59.4%$545.0M-19.7%$1.2B+67.9%-$693.0Mn/m
EPS (Basic)$1.35-16.7%$5.78+27.9%$9.85-4.5%-$6.60n/m$1.62-59.4%$4.52-19.7%$10.31+68.2%-$5.75n/m
EPS (Diluted)$1.33-17.9%$5.73+27.1%$9.83-4.6%-$6.59n/m$1.62-59.3%$4.51-19.8%$10.30+68.6%-$5.74n/m
Diluted Shares (Avg)122M+0.9%121M+0.3%121M-0.2%N/A121M0.0%121M+0.1%121M-0.3%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.

HUM Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HUM quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$57.3B+15.2%$57.2B+13.6%$55.3B+8.5%$48.9B+5.2%$49.7B-0.6%$50.4B+0.5%$50.9B+1.7%$46.5B-1.2%
Current Assets$39.6B+20.9%$40.1B+19.3%$38.1B+10.6%$32.7B+9.8%$32.8B-0.5%$33.6B+2.3%$34.4B+5.0%$29.8B-0.6%
Cash & Equivalents$6.9B+28.7%$6.9B+70.6%$5.0B+16.5%$4.2B+89.1%$5.4B+5.3%$4.0B-26.6%$4.3B-28.1%$2.2B-52.7%
Short-Term Investments$18.2B+8.6%$17.0B-3.9%$17.0B-4.9%$15.7B-13.8%$16.7B-12.1%$17.7B+1.4%$17.9B+7.1%$18.2B+9.6%
Long-Term Investments$606.0M+37.7%$650.0M+50.8%$626.0M+52.7%$493.0M+17.1%$440.0M+10.0%$431.0M+11.1%$410.0M+7.9%$421.0M+10.2%
Goodwill$10.5B+9.6%$10.5B+8.8%$10.5B+8.9%$9.7B+0.6%$9.6B+0.3%$9.6B+0.7%$9.6B+0.7%$9.6B+0.8%
Total Liabilities$38.4B+23.3%$37.9B+18.3%$36.6B+10.6%$31.2B+3.8%$31.1B-3.8%$32.1B-3.9%$33.1B-2.3%$30.0B-2.3%
Current Liabilities$24.1B+48.7%$23.0B+33.6%$21.5B+19.2%$16.3B-3.5%$16.2B-13.6%$17.2B-13.0%$18.0B-8.4%$16.9B-10.2%
Non-Current Liabilities$14.3B-4.1%$14.9B+0.5%$15.1B+0.4%$14.8B+13.2%$15.0B+9.5%$14.8B+9.3%$15.1B+6.0%$13.1B+10.3%
Long-Term Debt$11.6B-8.3%$12.0B-4.8%$12.3B-3.6%$12.4B+11.0%$12.6B+6.1%$12.6B+7.2%$12.7B+2.7%$11.1B+9.1%
Total Equity$18.8B+1.6%$19.2B+5.4%$18.6B+4.7%$17.7B+7.8%$18.5B+5.4%$18.2B+9.4%$17.8B+10.0%$16.4B+0.7%
Retained Earnings$30.8B+2.7%$30.7B+2.8%$30.2B+2.4%$29.1B+2.7%$30.0B+3.0%$29.9B+4.0%$29.5B+4.5%$28.3B+2.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable.

HUM Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HUM quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$2.2B+122.8%$2.0B+54.7%$1.3B+278.9%-$1.7Bn/m$971.0M-47.7%$1.3B+4.8%$331.0M-21.7%-$528.0Mn/m
Depreciation & Amortization$158.0M-8.7%$159.0M-10.7%$163.0M-10.9%$164.0M-21.2%$173.0M-17.6%$178.0M-16.0%$183.0M-12.4%$208.0M+3.5%
Stock-Based CompensationN/AN/A$51.0M+4.1%N/AN/AN/A$49.0M+8.9%N/A
Capital Expenditures$137.0M+1.5%$132.0M+15.8%$121.0M+27.4%$202.0M+31.2%$135.0M+3.8%$114.0M0.0%$95.0M-46.3%$154.0M-45.6%
Free Cash Flow$2.0B+142.3%$1.8B+58.5%$1.1B+380.1%-$1.9Bn/m$836.0M-51.6%$1.2B+5.3%$236.0M-4.1%-$682.0Mn/m
Investing Cash Flow-$2.1B-311.1%-$273.0M-178.7%-$2.6B-913.1%$632.0Mn/m$980.0Mn/m$347.0Mn/m$314.0Mn/m-$63.0Mn/m
Financing Cash Flow-$52.0Mn/m$249.0Mn/m$2.0B+48.1%-$168.0Mn/m-$603.0Mn/m-$1.8Bn/m$1.4B+14.7%-$2.3Bn/m
Dividends Paid$106.0M-0.9%$107.0M+0.9%$107.0M-0.9%$109.0M+0.9%$107.0M0.0%$106.0M-0.9%$108.0M-0.9%$108.0M-2.7%
Share Buybacks$2.0Mn/m$1.0M-99.0%$107.0M+1088.9%$42.0M-14.3%$0-100.0%$100.0M+104.1%$9.0M-98.7%$49.0M-91.4%

HUM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

HUM quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin0.2%-1.1pp3.3%-0.1pp4.4%-1.9pp-2.5%-0.6pp1.2%-1.3pp3.4%-0.5pp6.3%+2.1pp-1.9%-0.5pp
Net Margin0.4%-0.2pp1.7%0.0pp3.0%-0.9pp-2.5%-0.1pp0.6%-1.0pp1.7%-0.6pp3.9%+1.4pp-2.4%-0.3pp
Return on Equity0.9%-0.2pp3.6%+0.6pp6.4%-0.6pp-4.5%-0.3pp1.1%-1.7pp3.0%-1.1pp7.0%+2.4pp-4.2%-0.9pp
Return on Assets0.3%-0.1pp1.2%+0.1pp2.1%-0.3pp-1.6%-0.1pp0.4%-0.6pp1.1%-0.3pp2.4%+1.0pp-1.5%-0.3pp
Current Ratio1.65-0.4x1.74-0.2x1.77-0.1x2.00+0.2x2.02+0.3x1.95+0.3x1.91+0.2x1.76+0.2x
Debt-to-Equity0.61-0.1x0.62-0.1x0.66-0.1x0.700.0x0.680.0x0.690.0x0.72-0.1x0.68+0.1x
Liabilities-to-Equity2.04+0.4x1.97+0.2x1.97+0.1x1.77-0.1x1.68-0.2x1.76-0.2x1.87-0.2x1.83-0.1x
Asset Turnover0.72+0.1x0.71+0.1x0.72+0.1x0.660.0x0.66+0.1x0.64+0.1x0.630.0x0.63+0.1x
FCF Margin4.9%+2.4pp4.5%+0.9pp2.9%+2.1pp-5.7%-3.4pp2.6%-3.3pp3.6%-0.1pp0.7%-0.1pp-2.3%+25.7pp

Not reported in any period shown, so not listed: Gross Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Humana Inc. HUM FY2025 $129.7B $1.2B 0.9% $54.0B 49/100
Centene Corporation CNC FY2025 $194.8B -$6.7B -3.4% $35.3B 36/100
The Cigna Group CI FY2025 $274.9B $6.0B 2.2% $78.3B 50/100
Elevance Health, Inc. ELV FY2025 $199.1B $5.7B 2.8% $92.8B 48/100
CVS Health Corporation CVS FY2025 $402.1B $1.8B 0.4% $114.3B 34/100
Molina Healthcare, Inc. MOH FY2025 $45.4B $472.0M 1.0% $10.9B 63/100

Frequently Asked Questions

Humana Inc. (HUM) reported $129.7B in total revenue for fiscal year 2025. This represents a 10.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Humana Inc. (HUM) revenue grew by 10.1% year-over-year, from $117.8B to $129.7B in fiscal year 2025.

Yes, Humana Inc. (HUM) reported a net income of $1.2B over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $1.2B, with a net profit margin of 0.9%.

Humana Inc. (HUM) reported diluted earnings per share of $9.84 for fiscal year 2025. This represents a -1.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Humana Inc. (HUM) had EBITDA of $3.4B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Humana Inc. (HUM) had $4.2B in cash and equivalents against $12.4B in long-term debt.

Humana Inc. (HUM) had an operating margin of 2.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Humana Inc. (HUM) had a net profit margin of 0.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Yes, Humana Inc. (HUM) paid $3.54 per share in dividends during fiscal year 2025.

Humana Inc. (HUM) has a return on equity of 6.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Humana Inc. (HUM) generated $375.0M in free cash flow during fiscal year 2025. This represents a -84.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Humana Inc. (HUM) generated $921.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Humana Inc. (HUM) had $48.9B in total assets as of fiscal year 2025, including both current and long-term assets.

Humana Inc. (HUM) invested $546.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Yes, Humana Inc. (HUM) spent $151.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Humana Inc. (HUM) had 121M shares outstanding as of fiscal year 2025.

Humana Inc. (HUM) had a current ratio of 2.00 as of fiscal year 2025, which is generally considered healthy.

Humana Inc. (HUM) had a debt-to-equity ratio of 0.70 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Humana Inc. (HUM) had a liabilities-to-equity ratio of 1.77 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Humana Inc. (HUM) had a return on assets of 2.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Humana Inc. (HUM) trades at 43.4x earnings, its market capitalization divided by $1.2B net income, trailing 12 months to September 30, 2026. The market capitalization is $54.0B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Humana Inc. (HUM) trades at 0.4x sales, its market capitalization divided by $154.2B revenue, trailing 12 months to September 30, 2026. The market capitalization is $54.0B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Humana Inc. (HUM) has an Altman Z-Score of 5.11, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Humana Inc. (HUM) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Humana Inc. (HUM) has an earnings quality ratio of 0.78x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Humana Inc. (HUM) has an interest coverage ratio of 4.29x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Humana Inc. (HUM) scores 49 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top